Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 74 of the 74 references it cites were found in a registry or an index.

In vivo adenine base editing of PCSK9 in macaques reduces LDL cholesterol levels

Open access

Abstract

Most known pathogenic point mutations in humans are C•G to T•A substitutions, which can be directly repaired by adenine base editors (ABEs). In this study, we investigated the efficacy and safety of ABEs in the livers of mice and cynomolgus macaques for the reduction of blood low-density lipoprotein (LDL) levels. Lipid nanoparticle–based delivery of mRNA encoding an ABE and a single-guide RNA targeting PCSK9 , a negative regulator of LDL, induced up to 67% editing (on average, 61%) in mice and up to 34% editing (on average, 26%) in macaques. Plasma PCSK9 and LDL levels were stably reduced by 95% and 58% in mice and by 32% and 14% in macaques, respectively. ABE mRNA was cleared rapidly, and no off-target mutations in genomic DNA were found. Re-dosing in macaques did not increase editing, possibly owing to the detected humoral immune response to ABE upon treatment. These findings support further investigation of ABEs to treat patients with monogenic liver diseases.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41587-021-00933-4

Cites

74 of 74 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 In vivo adenine base editing of the Pcsk9 locus in the mouse liver. a, sgRNA target sequences in the mouse and macaque/human PCSK9 gene. The exonic region (exon 1) is highlighted in red; the intronic region is highlighted in black. The GT splice donor recognition site is highlighted in bold letters. The NGG-PAM site is indicated in blue. b, Schematic outline of the mouse experiments. Vectors were administered intravenously via tail vein injection in adult C57BL/6J mice. c, Percent editing after treatment with different ABE variants. Insertions and deletions are summarized as ‘Indels’. Values represent mean ± s.d. of n = 3, n = 2, n = 2 and n = 3 animals. d, Plasma Pcsk9 protein levels as determined by ELISA. ***P = 0.0002. e, Plasma LDL cholesterol levels. ***P = 0.0003. f, Background-subtracted absorbance (A450 – A540) representing the relative amount of anti-Cas9- or anti-TadA-specific plasma IgG antibodies as determined by ELISA. Positive control: plasma of TadA vaccinated animals or commercial Cas9-specific antibody at a concentration of 200 ng ml−1 (n = 2). g, Percent editing after treatment with different doses of LNP-encapsulated mRNA/sgRNA. Insertions or deletions are summarized as ‘Indels’. h, Plasma Pcsk9 protein levels as determined by ELISA. ****P < 0.0001. i, Plasma LDL cholesterol levels. ***P = 0.0004. j, Background-subtracted absorbance (A450 – A540) representing the relative amount of anti-Cas9- or anti-TadA-specific plasma antibodies as determined by ELISA. Positive control: plasma of TadA vaccinated animals or commercial Cas9-specific antibody at a concentration of 200 ng ml−1 (n = 2). Unless otherwise stated, values represent mean ± s.d. of n = 3 animals. Means were compared using two-tailed unpaired t-tests. vg, vector genomes.
Fig. 1 In vivo adenine base editing of the Pcsk9 locus in the mouse liver. a, sgRNA target sequences in the mouse and macaque/human PCSK9 gene. The exonic region (exon 1) is highlighted in red; the intronic region is highlighted in black. The GT splice donor recognition site is highlighted in bold letters. The NGG-PAM site is indicated in blue. b, Schematic outline of the mouse experiments. Vectors were administered intravenously via tail vein injection in adult C57BL/6J mice. c, Percent editing after treatment with different ABE variants. Insertions and deletions are summarized as ‘Indels’. Values represent mean ± s.d. of n = 3, n = 2, n = 2 and n = 3 animals. d, Plasma Pcsk9 protein levels as determined by ELISA. ***P = 0.0002. e, Plasma LDL cholesterol levels. ***P = 0.0003. f, Background-subtracted absorbance (A450 – A540) representing the relative amount of anti-Cas9- or anti-TadA-specific plasma IgG antibodies as determined by ELISA. Positive control: plasma of TadA vaccinated animals or commercial Cas9-specific antibody at a concentration of 200 ng ml−1 (n = 2). g, Percent editing after treatment with different doses of LNP-encapsulated mRNA/sgRNA. Insertions or deletions are summarized as ‘Indels’. h, Plasma Pcsk9 protein levels as determined by ELISA. ****P < 0.0001. i, Plasma LDL cholesterol levels. ***P = 0.0004. j, Background-subtracted absorbance (A450 – A540) representing the relative amount of anti-Cas9- or anti-TadA-specific plasma antibodies as determined by ELISA. Positive control: plasma of TadA vaccinated animals or commercial Cas9-specific antibody at a concentration of 200 ng ml−1 (n = 2). Unless otherwise stated, values represent mean ± s.d. of n = 3 animals. Means were compared using two-tailed unpaired t-tests. vg, vector genomes.CC BY · PubMed Central
Fig. 2 LNP-mediated ABE mRNA delivery leads to transient base editing without inducing substantial off-target deamination in the transcriptome. a, LNPs co-formulated with ABE mRNA and sgRNA_mP01 were systemically delivered. The top panel depicts ABEmax mRNA expression assessed by RT–qPCR. The middle panel depicts editing rates assessed by Sanger sequencing. The bottom panel depicts Pcsk9 mRNA levels assessed by RT–qPCR. The line represent mean of n = 2 animals per time point. b, Expression and localization of ABEmax mRNA 2 h or 12 h after injection of 3 mg kg−1 LNP assessed by smFISH in the liver. Twelve hours after injection, mRNA is predominantly cytoplasmatic. Blue, DAPI; white, ABEmax mRNA. Scale bar, top panel, 100 µm; scale bar, bottom panel, 20 µm. smFISH was performed once. c, Top, RNA-wide A-to-I editing assessed by whole-transcriptome sequencing. Each dot represents one editing event. The total number of editing events is indicated above. Each lane represents one individual biological replicate per animal. In vitro RNA-seq data are from HEK293T cells that were co-transfected with plasmids expressing ABEmax and sgRNA_mP01. Means of all replicates per sample were compared using one-tailed unpaired t-test for ex vivo samples and one-way ANOVA for in vivo samples. Bottom, telative TadA transcript expression in transcripts per million (TPM). NS, not significant.
Fig. 2 LNP-mediated ABE mRNA delivery leads to transient base editing without inducing substantial off-target deamination in the transcriptome. a, LNPs co-formulated with ABE mRNA and sgRNA_mP01 were systemically delivered. The top panel depicts ABEmax mRNA expression assessed by RT–qPCR. The middle panel depicts editing rates assessed by Sanger sequencing. The bottom panel depicts Pcsk9 mRNA levels assessed by RT–qPCR. The line represent mean of n = 2 animals per time point. b, Expression and localization of ABEmax mRNA 2 h or 12 h after injection of 3 mg kg−1 LNP assessed by smFISH in the liver. Twelve hours after injection, mRNA is predominantly cytoplasmatic. Blue, DAPI; white, ABEmax mRNA. Scale bar, top panel, 100 µm; scale bar, bottom panel, 20 µm. smFISH was performed once. c, Top, RNA-wide A-to-I editing assessed by whole-transcriptome sequencing. Each dot represents one editing event. The total number of editing events is indicated above. Each lane represents one individual biological replicate per animal. In vitro RNA-seq data are from HEK293T cells that were co-transfected with plasmids expressing ABEmax and sgRNA_mP01. Means of all replicates per sample were compared using one-tailed unpaired t-test for ex vivo samples and one-way ANOVA for in vivo samples. Bottom, telative TadA transcript expression in transcripts per million (TPM). NS, not significant.CC BY · PubMed Central
Fig. 3 In vivo adenine base editing of Pcsk9 does not induce substantial off-target mutations in DNA. a, Total number of A-to-G (including T-to-C) edits per genome. Clones from untreated control (n = 3), LNP-treated (n = 6) and AAV-treated (n = 6) mice. Box plots are standard Tukey plots. The centerline represents the median; the lower and upper hinges represent the first and third quartiles; and the whiskers represent ±1.5× the interquartile range. Two-tailed unpaired t-tests were used to compare means. b, Relative contributions of single-base substitutions in clones shown in a. Values represent mean ± s.d. Two-tailed unpaired t-tests were used to compare means. c, Heat map showing the cosine similarity of mutational signatures of control clones (untreated and CBE-treated) and ABE-treated clones (LNP and AAV) to a predetermined TadA signature39. 1 (match) and 0 (no similarity). For details on the clones, see Supplementary Fig. 6. In positive control clones, a TadA-specific trinucleotide mutation pattern39 was computationally added. d, sgRNA-dependent off-target sites of sgRNA-mP01 identified by CIRCLE-seq. The top ten off-target sites were analyzed by NGS in Hepa1-6 cells 5 d after transfection with plasmids encoding ABEmax and sgRNA_mP01 (in vitro) and in primary hepatocytes isolated from LNP-treated mice (3 mg kg−1, re-dose), AAV-treated mice (ABEmax) and untreated C57BL/6J mice. The second off-target site could not be determined (n.d.) owing to repetitiveness of the locus. Values represent the highest A-to-G conversion frequency within the protospacer. n = 3 biological replicates per treatment. e, Alb-Cre × Trp53flox/flox mice treated with AAVs expressing ABEmax and sgRNA_mP01 5 weeks after birth. Depicted is the HCC-free survival of mice. n = number of animals per group. f, Histopathology of liver samples from wild-type C57BL/6J animals and Alb-Cre × Trp53flox/flox animals. C57BL/6J animals untreated (n = 3), treated with LNP (n = 3) or treated with AAV (n = 3) were analyzed after 18 or 25 weeks, respectively. Alb-Cre × Trp53flox/flox animals untreated (n = 28), treated with control AAV (C-terminal part of the split system and a non-targeting sgRNA) (n = 18) or treated with the PCSK9-targeting AAV (n = 25) were analyzed after 1 year. H&E staining was performed on all animals; three pictures per animal were taken. Representative images are shown. (H&E; scale bar, 50 µm).
Fig. 3 In vivo adenine base editing of Pcsk9 does not induce substantial off-target mutations in DNA. a, Total number of A-to-G (including T-to-C) edits per genome. Clones from untreated control (n = 3), LNP-treated (n = 6) and AAV-treated (n = 6) mice. Box plots are standard Tukey plots. The centerline represents the median; the lower and upper hinges represent the first and third quartiles; and the whiskers represent ±1.5× the interquartile range. Two-tailed unpaired t-tests were used to compare means. b, Relative contributions of single-base substitutions in clones shown in a. Values represent mean ± s.d. Two-tailed unpaired t-tests were used to compare means. c, Heat map showing the cosine similarity of mutational signatures of control clones (untreated and CBE-treated) and ABE-treated clones (LNP and AAV) to a predetermined TadA signature39. 1 (match) and 0 (no similarity). For details on the clones, see Supplementary Fig. 6. In positive control clones, a TadA-specific trinucleotide mutation pattern39 was computationally added. d, sgRNA-dependent off-target sites of sgRNA-mP01 identified by CIRCLE-seq. The top ten off-target sites were analyzed by NGS in Hepa1-6 cells 5 d after transfection with plasmids encoding ABEmax and sgRNA_mP01 (in vitro) and in primary hepatocytes isolated from LNP-treated mice (3 mg kg−1, re-dose), AAV-treated mice (ABEmax) and untreated C57BL/6J mice. The second off-target site could not be determined (n.d.) owing to repetitiveness of the locus. Values represent the highest A-to-G conversion frequency within the protospacer. n = 3 biological replicates per treatment. e, Alb-Cre × Trp53flox/flox mice treated with AAVs expressing ABEmax and sgRNA_mP01 5 weeks after birth. Depicted is the HCC-free survival of mice. n = number of animals per group. f, Histopathology of liver samples from wild-type C57BL/6J animals and Alb-Cre × Trp53flox/flox animals. C57BL/6J animals untreated (n = 3), treated with LNP (n = 3) or treated with AAV (n = 3) were analyzed after 18 or 25 weeks, respectively. Alb-Cre × Trp53flox/flox animals untreated (n = 28), treated with control AAV (C-terminal part of the split system and a non-targeting sgRNA) (n = 18) or treated with the PCSK9-targeting AAV (n = 25) were analyzed after 1 year. H&E staining was performed on all animals; three pictures per animal were taken. Representative images are shown. (H&E; scale bar, 50 µm).CC BY · PubMed Central
Fig. 4 In vivo adenine base editing of the PCSK9 locus in the liver of macaques. a, Schematic outline of the experiments. Levels of ALT (b), TNF-α (b) and IP-10 (c). Day 15 is before re-dosing; Day 15, 6 h is 6 h after re-dosing. e, Histopathology of liver samples from untreated, 1.5 mg kg−1 single-dosed and 1.5 mg kg−1 re-dosed animals. Three different liver lobes of all animals of the high-dose groups were examined by a trained pathologist. Only very mild lobular mixed inflammatory cell infiltration was observed (white arrowhead). Black arrowheads indicate portal tracts. H&E; scale bar, 200 μm. f, Percent editing in treatment groups (six liver biopsies per animal analyzed). g, PCSK9 levels. Serum from two time points before (Day –12 and Day −1) and after (Day 22 and Day 29) treatment was analyzed. *P = 0.020 (1.5 mg kg−1); *P = 0.027 (1.5 mg kg−1 re-dose). h, LDL levels. Serum from two time points before (Day –12 and Day –1) and after (Day 22 and Day 29) treatment was analyzed. NS = 0.091; **P = 0.008. i, Background-subtracted absorbance (A450 – A540) representing the relative amount of anti-Cas9-specific IgG antibodies. 5% BSA coating was used to determine background levels. Means were compared to Day −1. *P = 0.0095. j, Background-subtracted absorbance (A450 – A540) representing the relative amount of anti-TadA-specific IgG antibodies. Means were compared to Day −1. *P = 0.0336, **P = 0.0026. k, Editing rates in DNA isolated from other tissues than the liver. l, sgRNA-dependent off-target sites of sgRNA_hP01 in the human genome identified using CIRCLE-seq. The top eight hits with orthologous sites in M. fasciularis were analyzed by NGS in vitro (HepG2 cells transfected with plasmids encoding ABEmax and sgRNA_hP01) and in vivo (3 mg kg−1 single-dosed and re-dosed). Values represent the highest A-to-G conversion frequency within the protospacer. n = 3 biological replicates per treatment. Control: DNA isolated from untreated HepG2 cells and macaque blood cells before treatment. MM, mismatches between the human and M. fasciularis genome. Values represent mean ± s.d. of n = 3 animals. Means were compared using one-tailed paired t-test.
Fig. 4 In vivo adenine base editing of the PCSK9 locus in the liver of macaques. a, Schematic outline of the experiments. Levels of ALT (b), TNF-α (b) and IP-10 (c). Day 15 is before re-dosing; Day 15, 6 h is 6 h after re-dosing. e, Histopathology of liver samples from untreated, 1.5 mg kg−1 single-dosed and 1.5 mg kg−1 re-dosed animals. Three different liver lobes of all animals of the high-dose groups were examined by a trained pathologist. Only very mild lobular mixed inflammatory cell infiltration was observed (white arrowhead). Black arrowheads indicate portal tracts. H&E; scale bar, 200 μm. f, Percent editing in treatment groups (six liver biopsies per animal analyzed). g, PCSK9 levels. Serum from two time points before (Day –12 and Day −1) and after (Day 22 and Day 29) treatment was analyzed. *P = 0.020 (1.5 mg kg−1); *P = 0.027 (1.5 mg kg−1 re-dose). h, LDL levels. Serum from two time points before (Day –12 and Day –1) and after (Day 22 and Day 29) treatment was analyzed. NS = 0.091; **P = 0.008. i, Background-subtracted absorbance (A450 – A540) representing the relative amount of anti-Cas9-specific IgG antibodies. 5% BSA coating was used to determine background levels. Means were compared to Day −1. *P = 0.0095. j, Background-subtracted absorbance (A450 – A540) representing the relative amount of anti-TadA-specific IgG antibodies. Means were compared to Day −1. *P = 0.0336, **P = 0.0026. k, Editing rates in DNA isolated from other tissues than the liver. l, sgRNA-dependent off-target sites of sgRNA_hP01 in the human genome identified using CIRCLE-seq. The top eight hits with orthologous sites in M. fasciularis were analyzed by NGS in vitro (HepG2 cells transfected with plasmids encoding ABEmax and sgRNA_hP01) and in vivo (3 mg kg−1 single-dosed and re-dosed). Values represent the highest A-to-G conversion frequency within the protospacer. n = 3 biological replicates per treatment. Control: DNA isolated from untreated HepG2 cells and macaque blood cells before treatment. MM, mismatches between the human and M. fasciularis genome. Values represent mean ± s.d. of n = 3 animals. Means were compared using one-tailed paired t-test.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

1 more claim about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 71 references

Cited by

See all 378

Metadata

Authors
Rothgangl, T., Dennis, M. K., Lin, P. J. C., Oka, R., Witzigmann, D., Villiger, L., Qi, W., Hruzova, M., Kissling, L., Lenggenhager, D., Borrelli, C., Egli, S., Frey, N., Bakker, N., Walker, J. A., Kadina, A. P., Victorov, D. V., Pacesa, M., Kreutzer, S., Kontarakis, Z., Moor, A., Jinek, M., Weissman, D., Stoffel, M., van Boxtel, R., Holden, K., Pardi, N., Thöny, B., Häberle, J., Tam, Y. K., Semple, S. C., & Schwank, G.
Affiliations
  • University of Zurich (CH)
  • Acuitas Therapeutics (Canada) (CA)
  • Oncode Institute (NL)
  • ETH Zurich (CH)
  • Synthego (United States) (US)
  • University of Pennsylvania (US)
  • University Children's Hospital Zurich (CH)
Corresponding author
  • Semple, Sean C.
  • Schwank, Gerald
Venue
Nature Biotechnology
Published
2021-05-19
Volume
39
Issue
8
Pages
949-957
ISSN
  • 0733-222X (ISSN-L)
  • 1087-0156
  • 1546-1696
OpenAlex
W3163681195
Cited by
378
References
71
Citations by year
2026: 48 · 2025: 74 · 2024: 76 · 2023: 76 · 2022: 82 · 2021: 22
FWCI
20.09
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Biotechnology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Pure Amsterdam UMC (publishedVersion, cc-by)
  • Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
  • Repository for Publications and Research Data (ETH Zurich) (submittedVersion, cc-by)
  • ETH Zürich Research Collection (cc-by)
Funders
  • Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (185293, 176088, 180257, 310030, 320030)
  • National Heart, Lung, and Blood Institute (R01HL134839)
  • National Institute of Allergy and Infectious Diseases (R01AI124429, U19AI142596)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA regulation and disease
Keywords
adenine base editing, PCSK9, LDL cholesterol, hypercholesterolemia, in vivo gene editing, liver, mRNA delivery, lipid nanoparticles, single guide RNA, cynomolgus macaques, mice, humoral immune response, off-target mutations
MeSH terms
Proprotein Convertase 9, Gene Editing, RNA, Guide, CRISPR-Cas Systems, Adenine, Animals, Cholesterol, LDL, Liver, Macaca, Male, Mice, Inbred C57BL, RNA, Guide, Kinetoplastida, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: In vivo adenine base editing of PCSK9 in macaques reduces LDL cholesterol levels. https://app.cochat.ai/papers/10.1038/s41587-021-00933-4
The paper
Rothgangl, T., Dennis, M. K., Lin, P. J. C., Oka, R., Witzigmann, D., Villiger, L., Qi, W., Hruzova, M., Kissling, L., Lenggenhager, D., Borrelli, C., Egli, S., Frey, N., Bakker, N., Walker, J. A., Kadina, A. P., Victorov, D. V., Pacesa, M., Kreutzer, S., . . . Schwank, G. (2021). In vivo adenine base editing of PCSK9 in macaques reduces LDL cholesterol levels. Nature Biotechnology. https://doi.org/10.1038/s41587-021-00933-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.